Abnormal macrophage response to microbial stimulus in a 43-year-old man with a severe form of atherosclerosis: a case report
© Conti et al; licensee BioMed Central Ltd. 2010
Received: 4 November 2009
Accepted: 18 June 2010
Published: 18 June 2010
New evidence indicates infections are emerging as risk factors for atherosclerosis although their specific role in the development and progression of atherosclerosis is still unclear.
A 43-year-old Caucasian man who had been treated for four years for multiple sclerosis progressively manifested systemic hypertension, polycythemia, peripheral arterial occlusion with intermittent claudication, and persistent headaches. In 2006, an instrumental analysis (magnetic resonance imaging) of our patient revealed widespread fibrocalcific atherosclerotic lesions which accounted for all his current symptoms, including those related to microbial stimulus. Two particular aspects were of interest, namely a lack of conventional cardiovascular risk factors and a negative family history for cardiovascular events. His chemical blood tests all yielded negative findings although a low positive hepatitis C virus-ribonucleic acid titer was detected. The titer had progressively increased and worsening atherosclerosis threatened the life of our patient. Interferon therapy was not appropriate for our patient due to the severe adverse effects observed shortly after its administration.
The reaction of individual cells to infections may provide an explanation as to why individuals with a similar microbial burden, corrected for the presence of other risk factors, display a different susceptibility to developing or worsening atherosclerosis. The identification of susceptible individuals and the treatment even of silent infections may provide an additional tool against atherosclerosis and its clinical complications. The evaluation of cell susceptibility before and after the correction of risk factors may contribute to the assessment of the efficacy of drug therapy.
Atherosclerosis is the leading cause of death in the majority of industrialized countries. The absence of "traditional" risk factors and the ready availability of new therapeutic options are not sufficient to provide overall protection against disease and its complications. Every effort is being made by the scientific community to identify conditions leading to disease of the arterial wall and to find new diagnostic procedures for identifying susceptible individuals. New lines of research have begun to show evidence to indicate that infectious agents are emerging as risk factors, although their role in the development and progression of atherosclerosis is still unclear.
Association of infections with atherosclerosis was first reported in the 1970s . Over the past decade awareness of the possible association between atherosclerosis and certain persistent bacterial and viral infections has steadily increased [2–6]. Numerous reports have referred to the contributory role in the atherosclerotic process played by periodontal diseases, which have often been associated with myocardial infarction and cerebrovascular events . However, this association does not necessarily prove the existence of atherogenic effects, particularly in view of the widespread distribution of the microorganisms involved.
Several authors have hypothesized that the number of different pathogens to which an individual has been exposed might promote a synergistic inflammatory response capable of exacerbating atherosclerosis [7–9].
A case of severe atherosclerosis in a 43-year-old patient who had no conventional risk factors, but with a known hepatitis C virus (HCV), infection and an abnormal immune cell response to infective stimuli, provided us with the opportunity to re-examine the impact of infections on cardiovascular diseases. In fact our case suggests that in patients with a similar microbial burden, but displaying a different susceptibility to atherosclerosis even in the presence of other risk factors, individual immune cell response to infective stimulus must be taken into account.
A 43-year-old Caucasian man was referred to the Department of Internal Medicine at the University Teaching Hospital in Cagliari. His clinical manifestations started in 2002 with a sudden onset of neurological symptoms. Magnetic resonance imaging (MRI) of lesions was consistent with a diagnosis of multiple sclerosis. Our patient, employed as a prison officer, was not deemed fit for work. In 2003, he was admitted to a small community hospital where he was also diagnosed with hypertension, polycythemia and intermittent claudication. Finally, in 2006, he was referred to the Multiple Sclerosis Centre at Cagliari University where a vascular origin was postulated for his neurological symptoms. Tests carried out on fibrocalcific atherosclerotic lesions accounted for the concomitant presence of systemic hypertension, polycythemia, brain injury and peripheral arterial occlusion. His electrocardiogram (ECG) findings were normal, although due to a compromised limb function, an exercise ECG could not be performed. Ethical reasons also dissuaded us from performing a coronary angiograph.
Clinical characteristics of our patient.
Total cholesterol (mmol/L)
2.3 (n.v. < 3.9)
9.5 pg/mL (n.v. < 15.6)
0.5 ( < 3.13)
HCV-RNA (IU/mL) genotype 1b
Ab anti-CMV IgG (IU)
5.6 (n.v. < 0.4)
Ab anti-CMV IgM (IU/mL)
8 (n.v. < 15)
Our patient was prescribed the following: interferon-gamma therapy was suspended to avoid its adverse effects; atenolol 10 mg/day; amlodipine 10 mg/day; cardio-aspirin 100 mg/day; lansoprazole 30 mg/day; allopurinol 300 μg/day; escitalopram 10 mg/day; and therapeutic bleeding about once a month.
HCV mRNA was first detected in 2006, the titer progressively increased but the criterion for interferon therapy was only reached in 2007. Unfortunately, the therapy was withdrawn because of the severe adverse effects observed shortly after its administration (aplastic myelosis, behavioral disturbance with depression, neurasthenia and anorexia). As our patient's lipids and systemic inflammatory markers were normal, it was not possible to prescribe conventional therapy to counteract the progression of his atherosclerosis. The disease is still worsening (the arterial tree has the appearance of being coated with wax) concomitantly with the increase in his HCV titer.
Despite an increasing number of studies performed to investigate the association between infections and vascular diseases, no consensus has been reached to date on the possible atherogenic effects of infectious agents. The pathogenetic mechanisms underlying this disease remain unclear, and the associations revealed do not necessarily prove the existence of atherogenic effects, particularly in view of the widespread distribution of the microorganisms involved.
This case report suggests that in susceptible individuals the presence of a chronic infective stimulus may directly activate metabolic pathways (such as cholesterol esterification) leading to foam cell formation and thus to atherosclerosis. Furthermore, it also implies that this condition may be exacerbated by acute infections, as is suggested by the exceedingly high rate of cholesterol esterification found in patient macrophages incubated with its own plasma plus LPS, but not found in control cells. Thus, in patients with a similar microbial burden who display a different susceptibility to atherosclerosis, even in the presence of other risk factors, individual immune cell response to infective stimulus should be taken into account.
To the best of our knowledge this is the first case that describes the molecular mechanisms by which macrophages respond to infective stimuli inducing foam cell formation. We suggest that research on silent infections and the evaluation of immune cell reactivity to microbial injuries, could lead to the development of an additional strategy for preventing and controlling atherosclerosis.
The reaction of individual cells to infections may provide an explanation as to why individuals with a similar microbial burden, corrected for the presence of other risk factors, display a different susceptibility to developing or worsening atherosclerosis. The identification of susceptible individuals and the treatment of silent infections may provide an additional tool against atherosclerosis and its clinical complications. The evaluation of cell susceptibility before and after the correction of risk factors may contribute to the assessment of the efficacy of drug therapy.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
hepatitis C virus
magnetic resonance imaging.
The authors thank Ms Anne Farmer for editing the manuscript's usage of the English language and Dr Silvana Puddu of the Centro Trasfusionale, Azienda Ospedaliera Brotzu, Cagliari, for preparing the buffy coats. The study was funded by Fondazione Banco di Sardegna, Regione Autonoma della Sardegna and Nutrisearch Srl (Italy).
- Fabricant CG, Fabricant J, Litrenta MM, Minick CR: Virus-induced atherosclerosis. J Exp Med. 1978, 148: 335-340. 10.1084/jem.148.1.335.View ArticlePubMed
- Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999, 34: 1975-1981. 10.1016/S0735-1097(99)00448-9.View ArticlePubMed
- Markus HS, Labrum R, Bevan S, Reindl M, Egger G, Wiedermann CJ, Xu O, Kiechl S, Willeit J: Genetic and acquired inflammatory conditions are synergistically associated with early carotid atherosclerosis. Stroke. 2006, 37: 2253-2259. 10.1161/01.STR.0000236637.72124.3f.View ArticlePubMed
- Mussa FF, Chai H, Wang X, Yao Q, Lumdsen AB, Chen C: Chlamydia pneumoniae and vascular disease: an update. J Vasc Surg. 2006, 43: 1031-1037. 10.1016/j.jvs.2006.02.050.View Article
- Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC: Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994, 71: 437-439. 10.1136/hrt.71.5.437.PubMed CentralView ArticlePubMed
- Blankenberg S, Rupprecht H-J, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J: Cytomegalovirus infection with interleukin-6 response predicts cardiovascular mortality in patients with coronary artery disease. Circulation. 2001, 103: 2915-2921.View ArticlePubMed
- Moutsopoulos NM, Madiasanos PN: Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci. 2006, 1088: 251-264. 10.1196/annals.1366.032.View ArticlePubMed
- Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S: Periodontal disease and cardiovascular disease. J Periodontal. 1996, 67: 1123-1137.View Article
- Soder PO, Soder B, Nowak J, Jogestrand T: Early carotid atherosclerosis in subjects with periodontal diseases. Stroke. 2005, 36: 1195-1200. 10.1161/01.STR.0000165916.90593.cb.View ArticlePubMed
- Rupprecht HJ, Blankerberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, Schlumberger W, Meyer J, AutoGene Investigators: Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001, 104: 25-31. 10.1161/hc2601.091703.View ArticlePubMed
- Stoll LL, Denning GM, Weintraub NL: Potential role of endotoxin as a pro-inflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004, 24: 2227-2236. 10.1161/01.ATV.0000147534.69062.dc.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.